表紙
市場調查報告書

痛風治療藥的全球市場:藥物類別,給藥途徑,流通管道,各地區 - 規模,佔有率,預測,及機會分析(2019年∼2027年)

Gout Disease Treatment Market, by Drug Class, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

出版商 Coherent Market Insights 商品編碼 918408
出版日期 內容資訊 英文 182 Pages
商品交期: 2-3個工作天內
價格
Back to Top
痛風治療藥的全球市場:藥物類別,給藥途徑,流通管道,各地區 - 規模,佔有率,預測,及機會分析(2019年∼2027年) Gout Disease Treatment Market, by Drug Class, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027
出版日期: 2019年11月22日內容資訊: 英文 182 Pages
簡介

本報告提供全球痛風治療藥市場的相關調查,提供市場機會和趨勢,成長及阻礙因素,各藥物類別·給藥途徑·流通管道·地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 調查目及前提條件

  • 調查目的
  • 前提條件
  • 簡稱

第2章 市場概要

  • 報告的說明
    • 市場定義·範圍
  • 摘要整理
    • 各藥物類別
    • 各給藥途徑
    • 各流通管道
    • 各地區
  • Coherent Opportunity Map (COM)

第3章 市場動態,法規,趨勢分析

  • 市場動態
    • 成長要素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 市場趨勢
  • 主要的開發
  • 合併·收購
  • 法規方案
  • 償付方案
  • PEST分析
  • 流行病學

第4章 市場分析:各類藥物

  • 簡介
  • 非類固醇消炎劑(NSAID)
  • 皮質類固醇
  • 秋水仙鹼
  • 降尿酸藥物
  • 單株抗體

第5章 市場分析:各給藥途徑

  • 簡介
  • 口服
  • 注射

第6章 市場分析:各流通管道

  • 簡介
  • 醫院藥局
  • 零售藥局
  • 線上藥局

第7章 市場分析:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 非洲
  • 中東

第8章 競爭情形

  • 熱圖分析
  • 企業簡介
    • AstraZeneca Plc
    • 武田藥品工業株式會社
    • Novartis International AG
    • Teijin製藥株式會社
    • Simcere Pharmaceutical
    • JW Pharmaceutical Corporation
    • Horizon Therapeutics plc
    • Hikma Pharmaceuticals Plc.
    • Ironwood Pharmaceuticals, Inc.
    • Zyla Life Sciences.
    • CymaBay Therapeutics, Inc..
  • 分析師的見解

第9章 章節

  • 參照資料
  • 調查方法
  • 關於本公司
目錄

Title:
Gout Disease Treatment Market, by Drug Class (Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Colchicine, Urate-lowering Agents, and Monoclonal Antibody), by Route of Administration (Oral and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027.

Gout is the chronic disease characterized by pain and inflammation in the joint. It is also known as gout arthritis, in which high level of uric acid in blood leads to formation of the needle-like crystals in the joints resulting into inflammation and pain. The conditions can be treated or prevented with use of the drugs such as nonsteroidal anti-inflammatory drugs, corticosteroids, colchicine, and urate-lowering agents. Moreover, monoclonal antibody is also used to treat gout for certain cases in which, nonsteroidal anti-inflammatory drugs, corticosteroids, colchicine, and urate lowering agents are unresponsive to the patient.

Market Dynamics

Increasing prevalence of gout disease is expected to increase demand of anti-gout drugs, which is expected to drive growth of the gout disease treatment market growth in forecast period. For instance, according to the National Center for Biotechnology Information (NCBI) (Rheumatology journal), the prevalence of gout in 2015 increased in South Korea compared to 2007 (earlier reported prevalence). In 2007, the prevalence of gout disease in South Korea was 3.49 (3.48-3.51) per 1,000 persons and in 2015, the prevalence of gout disease in South Korea was 7.58 (7.55-7.60) per 1,000 persons. Moreover, according to the data from the Australian Bureau of Statistics 2017-2018 (a National Health Survey), an estimated 187,000 people of Australia (0.8% of the Australia population) were diagnosed with gout disease in 2017.

Key features of the study:

  • This report provides in-depth analysis of the global gout disease treatment market, market size (US$ Mn), and compound annual growth rate (CAGR %) over the forecast period (2019 - 2027), considering 2018, as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrixes for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new technology launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles leading players in the global gout disease treatment market based on the following parameters - company overview, financial performance, technology portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include AstraZeneca Plc, Takeda Pharmaceutical Company Limited, Novartis International AG, Teijin Pharma Limited, Simcere Pharmaceutical, JW Pharmaceutical Corporation, Horizon Therapeutics plc., Hikma Pharmaceuticals Plc, Ironwood Pharmaceuticals, Inc., CymaBay Therapeutics, Inc., and Zyla Life Sciences
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future technology launches, governmental initiatives, technological up-gradation, market expansions, and marketing tactics
  • The global gout disease treatment market report caters to various stakeholders in this market, including investors, technology manufacturers, distributors, and suppliers in the global ophthalmic viscoelastic devices industry, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

Global Gout Disease Treatment Market, By Drug Class:

  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Colchicine
  • Urate-lowering Agents
  • Monoclonal Antibody

Global Gout Disease Treatment Market, By Route of Administration:

  • Oral
  • Injectable

Global Gout Disease Treatment Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Global Gout Disease Treatment Market, By Region:

North America

  • By Country:
    • U.S.
    • Canada
  • By Drug Class:
    • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • Corticosteroids
    • Colchicine
    • Urate-lowering Agents
    • Monoclonal Antibody
  • By Route of Administration:
    • Oral
    • Injectable
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Europe

  • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
  • By Drug Class:
    • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • Corticosteroids
    • Colchicine
    • Urate-lowering Agents
    • Monoclonal Antibody
  • By Route of Administration:
    • Oral
    • Injectable
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Asia Pacific

  • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
  • By Drug Class:
    • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • Corticosteroids
    • Colchicine
    • Urate-lowering Agents
    • Monoclonal Antibody
  • By Route of Administration:
    • Oral
    • Injectable
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Latin America

  • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • By Drug Class:
    • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • Corticosteroids
    • Colchicine
    • Urate-lowering Agents
    • Monoclonal Antibody
  • By Route of Administration:
    • Oral
    • Injectable
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Middle East

  • By Country:
    • GCC
    • Israel
    • Rest of Middle East
  • By Drug Class:
    • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • Corticosteroids
    • Colchicine
    • Urate-lowering Agents
    • Monoclonal Antibody
  • By Route of Administration:
    • Oral
    • Injectable
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Africa

  • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
  • By Drug Class:
    • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • Corticosteroids
    • Colchicine
    • Urate-lowering Agents
    • Monoclonal Antibody
  • By Route of Administration:
    • Oral
    • Injectable
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Company Profiles:

  • AstraZeneca Plc*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
      • Takeda Pharmaceutical Company Limited
      • Novartis International AG
      • Teijin Pharma Limited
      • Simcere Pharmaceutical
      • JW Pharmaceutical Corporation
      • Horizon Therapeutics plc
      • Hikma Pharmaceuticals Plc.
      • Ironwood Pharmaceuticals, Inc.
      • CymaBay Therapeutics, Inc.
      • Zyla Life Sciences

"*" marked represents similar segmentation in other categories in the respective section

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Route of Administration
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Mergers and Acquisitions
  • Regulatory Scenario
  • Reimbursement Scenario
  • PEST Analysis
  • Epidemiology

4. Global Gout Disease Treatment Market, By Drug Class, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Corticosteroids
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Colchicine
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million) Corticosteroids
  • Urate-lowering Agents
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Monoclonal Antibody
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

5. Global Gout Disease Treatment Market, By Route of Administration, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Injectable
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

6. Global Gout Disease Treatment Market, By Distribution Channel, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

7. Global Gout Disease Treatment Market, By Region, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2027
    • Regional Trends
  • North America
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country/Region, 2016 - 2027, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa
  • Middle East
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East

8. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • AstraZeneca Plc
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Takeda Pharmaceutical Company Limited
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Novartis International AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Teijin Pharma Limited
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Simcere Pharmaceutical
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • JW Pharmaceutical Corporation
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Horizon Therapeutics plc
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Hikma Pharmaceuticals Plc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Ironwood Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Zyla Life Sciences.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • CymaBay Therapeutics, Inc..
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Analyst Views

9. Section

  • References
  • Research Methodology
  • About us and Sales Contact
Back to Top